# Phase 2 Biliary Tract cancer trials recruiting: 63 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 63 trials in phase 2 for Biliary Tract cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Biliary Tract cancer trials: 63 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/biliary-tract-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 63
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07938645 | PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 | Not yet recruiting | Biliary Tract Cancer (BTC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938645) |
| November 16, 2026 | NCT07938021 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC) | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938021) |
| November 2, 2026 | NCT07908550 | Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer | National Health Research Institutes, Taiwan | Phase 2 | Not yet recruiting | Biliary Tract Cancer (BTC) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908550) |
| October 26, 2026 | NCT07893392 | Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Biliary Tract Cancer (BTC), Surgery, Radiotherapy | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893392) |
| October 2, 2026 | NCT07854600 | A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854600) |
| September 30, 2026 | NCT07850791 | A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850791) |
| September 25, 2026 | NCT07841873 | Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors | Anhui Provincial Hospital | Phase 2 | Not yet recruiting | Biliary Tract Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841873) |
| September 21, 2026 | NCT07831993 | Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | Recruiting | Biliary Tract Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831993) |
| September 21, 2026 | NCT07829874 | Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. | Fudan University | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829874) |
| September 1, 2026 | NCT07797816 | Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | Recruiting | Biliary Tract Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797816) |
| August 28, 2026 | NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793253) |
| August 26, 2026 | NCT07786766 | Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786766) |
| July 29, 2026 | NCT07733115 | QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer | Shanghai Zhongshan Hospital | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733115) |
| July 27, 2026 | NCT07729033 | A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Advanced Biliary Tract Cancers | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729033) |
| July 24, 2026 | NCT07726446 | Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Biliary Tract Cancer (BTC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726446) |
| July 15, 2026 | NCT07704177 | Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract... | Peking Union Medical College Hospital | Phase 2 | Recruiting | Biliary Tract Neoplasms Immunotherapy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704177) |
| July 14, 2026 | NCT07701122 | Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Advanced Biliary Tract Cancer(BTC) | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701122) |
| July 1, 2026 | NCT07679399 | A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract... | Peking Union Medical College Hospital | Phase 2 | Recruiting | Biliary Tract Neoplasms Immunotherapy | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679399) |
| June 26, 2026 | NCT07670273 | Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low... | Peking Union Medical College Hospital | Phase 2 | Recruiting | Biliary Tract Neoplasms Immunotherapy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670273) |
| June 25, 2026 | NCT07668453 | An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Biliary Tract Neoplasms | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668453) |
| June 16, 2026 | NCT07649980 | Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Biliary Tract Cancer (BTC), EGFR-positive Advanced Biliary Tract Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649980) |
| June 10, 2026 | NCT07638501 | Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer | Eastern Hepatobiliary Surgery Hospital | Phase 2 | Not yet recruiting | Biliary Tract Cancer (BTC) | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638501) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| May 20, 2026 | NCT07599995 | Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies | Sir Run Run Shaw Hospital | Phase 2 | Not yet recruiting | Biliary Tract Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599995) |
| May 6, 2026 | NCT07569679 | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer | Air Force Military Medical University, China | Phase 2 | Recruiting | Biliary Tract Cancer | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569679) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Peking Union Medical College Hospital | 7 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| Shanghai Zhongshan Hospital | 3 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Fudan University | 2 |
| The Second Affiliated Hospital of Shandong First Medical University | 2 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Asan Medical Center | 1 |
| Harbin Medical University | 1 |
| Replimune, Inc. | 1 |
| Fujian Cancer Hospital | 1 |
| University of Texas Southwestern Medical Center | 1 |
| 3D Medicines (Sichuan) Co., Ltd. | 1 |
| Air Force Military Medical University, China | 1 |
| Sir Run Run Shaw Hospital | 1 |
| Shanghai Guangsheng Biopharmaceutical Co., Ltd | 1 |
| Sun Yat-sen University | 1 |
| National Cheng-Kung University Hospital | 1 |
| University Health Network, Toronto | 1 |
| Eastern Hepatobiliary Surgery Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 38 |
| United States | 8 |
| South Korea | 5 |
| Canada | 5 |
| France | 4 |
| Spain | 4 |
| Taiwan | 4 |
| United Kingdom | 4 |
| Italy | 3 |
| Japan | 3 |
| Australia | 3 |
| Germany | 2 |
| Poland | 2 |
| Switzerland | 2 |
| Turkey (Türkiye) | 1 |
| Netherlands | 1 |
| Norway | 1 |
| Sweden | 1 |
| Denmark | 1 |
| Georgia | 1 |
| Malaysia | 1 |
| Moldova | 1 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratory equipment suppliers in the United States](https://specstream.ai/data/businesses/laboratory-equipment-suppliers/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
